David G Brachman1, Stephanie L Pugh2, Lynn S Ashby3, Theresa A Thomas4, Erin M Dunbar5, Samir Narayan6, H Ian Robins7, Joseph A Bovi8, Jason K Rockhill9, Minhee Won3, Walter P Curran10. 1. Arizona Oncology Services Foundation, Scottsdale, Arizona; Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona. Electronic address: david.brachman@dignityhealth.org. 2. Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania. 3. Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona. 4. Arizona Oncology Services Foundation, Scottsdale, Arizona. 5. University of Florida College of Medicine, Gainesville, Florida. 6. St. Joseph Mercy Hospital, Ann Arbor, Michigan. 7. University of Wisconsin Hospital, Madison, Wisconsin. 8. Medical College of Wisconsin, Milwaukee, Wisconsin. 9. University of Washington Medical Center, Seattle, Washington. 10. Emory University, Atlanta, Georgia.
Abstract
PURPOSE: The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and radiation therapy (RT) in patients with newly diagnosed supratentorial glioblastoma multiforme (GBM). Phase 2 determined whether this combination improved overall survival (OS) and progression-free survival (PFS) in GBM recursive partitioning analysis class III to V patients compared to therapies for recently published historical controls. METHODS AND MATERIALS: Dose escalation in phase 1 progressed through 3 cohorts until 2 of 6 patients experienced dose-limiting toxicity or a dose of 5 mg/kg was reached. Once MTD was established, a 1-sided 1-sample log-rank test at significance level of .1 had 85% power to detect a median survival difference (13.69 vs 18.48 months) with 60 deaths over a 12-month accrual period and an additional 18 months of follow-up. OS and PFS were estimated using the Kaplan-Meier method. RESULTS: In phase 1, 24 patients were enrolled. The MTD established was 5 mg/kg, given intravenously 5 days a week for the first 10 RT fractions, then 3 times a week for the duration of RT. The 7 patients enrolled in the third dose level and the 94 enrolled in phase 2 received this dose. Of these 101 patients, 87 were eligible and evaluable. Median survival time was 15.6 months (95% confidence interval [CI]: 12.9-17.6 months), not significantly different from that of the historical control (P=.36). Median PFS was 7.6 months (95% CI: 5.7-9.6 months). One patient (1%) experienced a grade 5 adverse event possibly related to therapy during the concurrent phase, and none experience toxicity during adjuvant TMZ therapy. CONCLUSIONS: Treatment was well tolerated, but median OS did not reach improvement specified by protocol compared to historical control, indicating that the combination of standard RT with TMZ and MGd did not achieve a significant survival advantage.
PURPOSE: The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and radiation therapy (RT) in patients with newly diagnosed supratentorial glioblastoma multiforme (GBM). Phase 2 determined whether this combination improved overall survival (OS) and progression-free survival (PFS) in GBM recursive partitioning analysis class III to V patients compared to therapies for recently published historical controls. METHODS AND MATERIALS: Dose escalation in phase 1 progressed through 3 cohorts until 2 of 6 patients experienced dose-limiting toxicity or a dose of 5 mg/kg was reached. Once MTD was established, a 1-sided 1-sample log-rank test at significance level of .1 had 85% power to detect a median survival difference (13.69 vs 18.48 months) with 60 deaths over a 12-month accrual period and an additional 18 months of follow-up. OS and PFS were estimated using the Kaplan-Meier method. RESULTS: In phase 1, 24 patients were enrolled. The MTD established was 5 mg/kg, given intravenously 5 days a week for the first 10 RT fractions, then 3 times a week for the duration of RT. The 7 patients enrolled in the third dose level and the 94 enrolled in phase 2 received this dose. Of these 101 patients, 87 were eligible and evaluable. Median survival time was 15.6 months (95% confidence interval [CI]: 12.9-17.6 months), not significantly different from that of the historical control (P=.36). Median PFS was 7.6 months (95% CI: 5.7-9.6 months). One patient (1%) experienced a grade 5 adverse event possibly related to therapy during the concurrent phase, and none experience toxicity during adjuvant TMZ therapy. CONCLUSIONS: Treatment was well tolerated, but median OS did not reach improvement specified by protocol compared to historical control, indicating that the combination of standard RT with TMZ and MGd did not achieve a significant survival advantage.
Authors: Darren Magda; Philip Lecane; Richard A Miller; Cheryl Lepp; Dale Miles; Mimi Mesfin; John E Biaglow; Vincent V Ho; Danny Chawannakul; Shailender Nagpal; Mazen W Karaman; Joseph G Hacia Journal: Cancer Res Date: 2005-05-01 Impact factor: 12.701
Authors: Michael A Vogelbaum; Sarah Jost; Manish K Aghi; Amy B Heimberger; John H Sampson; Patrick Y Wen; David R Macdonald; Martin J Van den Bent; Susan M Chang Journal: Neurosurgery Date: 2012-01 Impact factor: 4.654
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Minesh P Mehta; Patrick Rodrigus; C H J Terhaard; Aroor Rao; John Suh; Wilson Roa; Luis Souhami; Andrea Bezjak; Mark Leibenhaut; Ritsuko Komaki; Christopher Schultz; Robert Timmerman; Walter Curran; Jennifer Smith; See-Chun Phan; Richard A Miller; Markus F Renschler Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Walter Taal; Joyce M W Segers-van Rijn; Johan M Kros; Irene van Heuvel; Carin C D van der Rijt; Jacoline E Bromberg; Peter A E Sillevis Smitt; Martin J van den Bent Journal: J Neurooncol Date: 2012-03-07 Impact factor: 4.130
Authors: Anqi Yao; Sarah J Storr; Martyn Inman; Lucy Barwell; Christopher J Moody; Stewart G Martin Journal: Mol Neurobiol Date: 2022-03-28 Impact factor: 5.682
Authors: Md Yousuf Ali; Claudia R Oliva; Abu Shadat M Noman; Bryan G Allen; Prabhat C Goswami; Yousef Zakharia; Varun Monga; Douglas R Spitz; John M Buatti; Corinne E Griguer Journal: Cancers (Basel) Date: 2020-09-03 Impact factor: 6.639
Authors: Natalia V Pozdniakova; Oxana V Ryabaya; Alevtina S Semkina; Vsevolod A Skribitsky; Alexei B Shevelev Journal: Int J Mol Sci Date: 2022-03-18 Impact factor: 5.923